Meeting ReportsTherapeutics Development

Leveraging Crowdsourcing to Facilitate the Discovery of New Medicines

See allHide authors and affiliations

Science Translational Medicine  22 Jun 2011:
Vol. 3, Issue 88, pp. 88mr1
DOI: 10.1126/scitranslmed.3002678

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Visions and Revisions

Like the risk-averse namesake in the poem The Love Song of J. Alfred Prufrock, the pharmaceutical industry may be poised to see “the moment of [its] greatness flicker” if it doesn’t “dare disturb the universe.” This wake-up call has spurred scientists, policy makers, foundations, and funders to devise innovative models of drug discovery. The nascent public-private partnership (PPP) Arch2POCM aims to advance drug development through the validation of pioneer therapeutic targets for human diseases in an open-access environment void of intellectual property (IP). At Arch2POCM’s recent meeting in April 2011, participants experienced a “eureka” moment—that crowdsourcing of their IP-free findings and reagents has the potential to provide clinical information about the pioneer targets in many indications and thereby mitigate some of the risk associated with therapeutics discovery and development. Here, the authors relate how Arch2POCM hopes to harness progressive minds worldwide to reinvent the drug discovery progress—and eventually transform clinical medicine.


  • Citation: T. C. Norman, C. Bountra, A. M. Edwards, K. R. Yamamoto, S. H. Friend, Leveraging Crowdsourcing to Facilitate the Discovery of New Medicines. Sci. Transl. Med. 3, 88mr1 (2011).

View Full Text

Stay Connected to Science Translational Medicine